Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.

Rorick-Kehn, Linda M; Perkins, Everett J; Knitowski, Karen M; Hart, John C; Johnson, Bryan G; Schoepp, Darryle D; McKinzie, David L

Rorick-Kehn, Linda M; Perkins, Everett J; Knitowski, Karen M; Hart, John C; Johnson, Bryan G; Schoepp, Darryle D; McKinzie, David L.

Affiliation

Rorick-Kehn LM; Neuroscience Discovery Research Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.

J Pharmacol Exp Ther ; 316(2): 905-13, 2006 Feb.

Article in En | MEDLINE | ID: mdl-16223873

Subject(s)

Behavior, Animal/drug effects; Bridged Bicyclo Compounds; Prodrugs; Receptors, Metabotropic Glutamate/agonists; Administration, Oral; Alanine/analogs & derivatives; Alanine/pharmacokinetics; Alanine/pharmacology; Animals; Biological Availability; Body Temperature/drug effects; Bridged Bicyclo Compounds/pharmacokinetics; Bridged Bicyclo Compounds/pharmacology; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred DBA; Motor Activity/drug effects; Prodrugs/pharmacokinetics; Prodrugs/pharmacology; Rats; Rats, Sprague-Dawley; Stress, Physiological/physiopathology; Time Factors

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Behavior, Animal / Bridged Bicyclo Compounds / Prodrugs / Receptors, Metabotropic Glutamate Type of study: Prognostic_studies Limits: Animals Language: En Journal: J Pharmacol Exp Ther Year: 2006 Document type: Article

Search on Google

XML

PubMed Links